APA (7th ed.) Citation

JM, B., N, J., CM, M., RA, S., A, C., D, C., . . . HJL, H. (2025). Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial. Diabetes, obesity & metabolism, 27(8), 4415. https://doi.org/10.1111/dom.16478

Chicago Style (17th ed.) Citation

JM, Beernink, et al. "Effects of Dapagliflozin on Sodium Excretion, Blood Pressure and Volume Status in Patients with Type 2 Diabetes And/or Chronic Kidney Disease: The DAPASALT Trial." Diabetes, Obesity & Metabolism 27, no. 8 (2025): 4415. https://doi.org/10.1111/dom.16478.

MLA (9th ed.) Citation

JM, Beernink, et al. "Effects of Dapagliflozin on Sodium Excretion, Blood Pressure and Volume Status in Patients with Type 2 Diabetes And/or Chronic Kidney Disease: The DAPASALT Trial." Diabetes, Obesity & Metabolism, vol. 27, no. 8, 2025, p. 4415, https://doi.org/10.1111/dom.16478.